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1.	Introduction	
 
1.1 Pemphigoid diseases of the skin 
 
Pemphigoid diseases of the skin are a group of diverse diseases characterized by the 
presence of IgG autoantibodies (auto-ab) against different proteins of hemidesmosomes 
in the dermal epidermal junction (DEJ) of the skin and mucosa. Targeted proteins play a 
major role in the structural integrity of the skin and mucosa, so that targeting of these 
proteins by auto-ab leads to alteration of the basal membrane with the formation of 
blisters, erosions, papules, often supported by concomitant inflammatory skin infiltrates. 
The pemphigoids encompass distinct subtypes, bullous pemphigoid (BP) is the most 
common clinical subtype and is characterized by the presence of IgG auto-ab against the 
hemidesmosomal adhesion molecules, BP180 and BP230. Other subtypes include 
pemphigoid gestationis, linear IgA disease (LAD), mucous membrane pemphigoid 
(MMP), laminin gamma-1 (Lam γ-1) pemphigoid and epidermolysis bullosa acquisita 
(EBA). These diseases may be clinically hard to differentiate, since they often present 
clinical similarity, nonetheless the starting point for the discrimination between these 
different diseases is the correct diagnosis. It is crucial to differentiate between the 
different entities since different subtypes present also different target antigens, different 
prognosis and may require different treatment. For the proper diagnosis of the different 
clinical manifestations of pemphigoid diseases, it is critical to establish reliable 
serological tools for the detection of serum auto-ab against components of the DEJ.  
 
1.2 Laminin γ-1 pemphigoid 
 
Lam γ-1 pemphigoid is a rare variant of the pemphigoids which have been recently 
described as an autoimmune response against the γ chain of laminins (Dainichi, Kurono 
et al. 2009, Dainichi, Koga et al. 2010). The disease was independently described in 1996 
by Zillikens et al. and Chen et al. as a new uncharacterized type of pemphigoid which 
was characterized by the presence of circulating reactive IgG auto-ab against a 200-kDa 
component of the DEJ. Therefore, the disease was firstly named anti p-200 pemphigoid 
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(Chen, Shimizu et al. 1996, Zillikens, Kawahara et al. 1996). Serologically, the disease 
was characterized by the presence of linear IgG and C3 deposits by direct 
immunofluorescence (DIF) along the DEJ, while indirect immunofluorescence (IIF) 
showed dermal binding of serum IgG auto-ab on saline split human skin (SSS) (Meijer, 
Diercks et al. 2016). The latter finding differentiated this entity from BP, associating the 
disorder to EBA and MMP, since both show a similar staining pattern by IIF (Meijer, 
Diercks et al. 2016). Further investigations eventually showed that the non-collagenous 
p-200 was different from other known autoantigens and was identified as the γ-1 chain of 
laminins, leading to the final denomination of lam γ-1 pemphigoid by some groups 
(Solimani, Pollmann et al. 2018). Clinically, the disease has a variable appearance,  it 
may resemble BP since it is associated with strong pruritus, presence of tense blisters 
which are mostly located on the extremities, papules, vesicles and urticarial plaques are 
frequently observed (Goletz, Hashimoto et al. 2014, Amber, Murrell et al. 2018). 
Nonetheless, Lam γ-1 pemphigoid may mimic other related bullous diseases such as 
dermatitis herpetiformis Duhring or in rare cases, the inflammatory type of EBA. 
Therefore a reliable diagnostic method is crucial to establish the correct diagnosis (Meijer, 
Diercks et al. 2016, Amber, Murrell et al. 2018, Solimani, Pollmann et al. 2018). Given 
the rarity of the disease and the difficulty to correctly diagnose this entity, there is a lack 
of good epidemiological data. So far around 100 cases of patients affected by Lam γ-1 
pemphigoid cases have been published.  The disease seems to have a more benign clinical 
course as BP. On the other hand, patients with Lam γ-1 pemphigoid are younger than BP 
patients (Dilling, Rose et al. 2007, Goletz, Hashimoto et al. 2014).  Furthermore, Lam γ-
1 pemphigoid is associated with psoriasis vulgaris (Chen, Shimizu et al. 1996, McFadden, 
Powles et al. 2013, Ohata, Ishii et al. 2015). A pathophysiological link between the two 
diseases has not yet been found (McFadden, Powles et al. 2013).  Lastly, it seems that 
only a minority of patients affected by Lam γ-1 pemphigoid present concomitant 
involvement of the mucous membranes (Goletz, Hashimoto et al. 2014). Histologically 
there is a subepidermal loss of adhesion with a superficial inflammatory infiltrate 
consisting of eosinophils and/or neutrophils which resembles BP or LAD (Dilling, Rose 
et al. 2007). Although the pathogenicity of Lam γ-1-specific IgG has not yet been shown 
neither in vivo nor in vitro recombinants of the  Lam γ-1 chain show prognosis as a reliable 
3
 
 
target to serologically diagnose this rave variant (Koga, Ishii et al. 2013, Florea, Bernards 
et al. 2014). 
 
1.3 Epidermolysis Bullosa Acquisita 
 
EBA is a severe autoimmune disease with a chronic recalcitrant course which affects 
approximately 1-5 cases per million people. The disease has been firstly described by 
Eliott in 1895 (Kim and Kim 2013). Serologically, EBA is characterized by the presence 
of IgG auto-ab against human type VII collagen  (ColVII) and by the detection of sera 
IgG binding to the dermal side of SSS. ColVII is the major component of anchoring 
fibrils, proteins which play a crucial role for the integrity of the skin (Stanley, Woodley 
et al. 1984). The binding of anti ColVII IgG leads to a destabilization of the anchoring 
fibrils and consecutively to a pronounced skin fragility and dermal loss of adhesion. 
ColVII is a collagenous protein with three trimers all consisting of a NH2-terminal (NC1) 
and a COOH-terminal (NC2) domain (Bentz, Morris et al. 1983). Although most of the 
patients show circulating IgG autoantibodies against the NC1 domain (Lapiere, Woodley 
et al. 1993), the NC2 domain is also targeted by EBA sera (Chen, Remmler et al. 1993, 
Fukumoto, Umekawa et al. 2004, Ishii, Yoshida et al. 2004). EBA has a mean onset of 
50 years and two major clinical variants have been described: 1) a mechanobullous 
phenotype which resembles dystrophic EB with acral blistering and presence of scarring 
and milia and of hyper- and/or hypopigmentation and 2) an inflammatory type, which is 
characterized by a BP-like inflammatory phenotype, associated with complement 
activation and dermal neutrophil recruitment (Kim and Kim 2013). Treatment of EBA is 
often challenging due to its recalcitrant clinical course and prolonged skin fragility. 
Treatment is based mainly on systemic corticosteroids, frequently combined with 
immunosuppressive adjuvants such as mycophenolate mofetil, azathioprine or 
methotrexate (Gurcan and Ahmed 2011, Kim, Kim et al. 2011). Recently, treatment with 
high dose intravenous immunoglobulins, immunoadsorption and the anti-CD20 
monoclonal antibody, rituximab, have been tried with variable success (Schmidt, Benoit 
et al. 2006, Schmidt and Zillikens 2010, Kim, Lee et al. 2012). Generally, the 
inflammatory type of EBA shows a better response to immunosuppressive agents. 
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However, the clinical presentation per se is not sufficient to correctly diagnose 
inflammatory EBA. This rare entity may mimic EB, BP, LAD and pemphigus vulgaris 
(PV). Therefore, serological detection of IgG against ColVII is crucial to correctly 
establish the diagnosis of EBA (Schmidt and Zillikens 2010). 
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2 Summary of published results 
 
2.1 Study I: Diagnosis of anti-laminin γ -1 pemphigoid by immunoblot analysis 
 
 
 
Impact factor (I.F): 4.287, own contribution 80% 
F. S wrote the manuscript, performed the experiments, analysed data, designed figures, 
and recruited the patients. R. E. and M. H designed and supervised the study. T. H and N. 
I provided sera from their respective centres. R. P, T. S, R. E and M. H analysed data and 
revised the study. All authors revised and finally approved the manuscript  
A part of the experiments (western blots analysis) was performed by Elke Herrmann, a 
medical technician in the Department of Dermatology and Allergology at the University 
of Marburg. 
 
Given the lack of easily reproducible methods for the detection of IgG auto-ab against 
Lam γ-1, the scope of this study was to develop an easy-to-perform and reliable immune 
serological assay based on commercially available recombinant of Lam γ-1. In the present 
study, we developed a novel viable method for the serological detection of auto-ab against 
Lam γ-1d.  To verify our diagnostic assay, we tested sera of Lam γ-1 pemphigoid patients 
by immunoblot (IB) analysis with three different proteins: two recombinant 
heterotrimers, namely Lam-111 and Lam 421, as well as with a recombinant Lam γ-1 
chain monomer. To assess the specificity and sensitivity of IB analysis, we tested sera of 
55 patients with Lam γ-1 pemphigoid and of 41 control sera, specifically 14 sera of 
patients with psoriasis vulgaris (Pso V.), 15 EBA sera and 12 healthy controls (HC) sera. 
The results of our IB analysis showed that 84% of the Lam γ-1 pemphigoid patients 
showed reactivity with Lam-111 and/or Lam-421 (46/55 patients). In a second step, the 9 
non-reactive sera were tested with the Lam γ-1 monomer, in total 8/9 sera reacted with 
the Lam γ-1 monomer leading to an overall sensitivity of the combined IB assays of 
F. Solimani, R. Pollmann, N. Ishii, R. Eming, T. Hashimoto, T. Schmidt,  M. Hertl 
J Eur Acad Dermatol Venereol 2019 Apr;33(4):735-741 
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98.2%. Control sera were also tested with the three recombinant Lam γ-1 proteins 
showing a specificity of 88%. Specifically, 3/15 EBA sera, 1/14 Pso V sera and 1/12 HC 
sera reacted with the Lam γ-1 monomer, the three EBA sera reacted also against the Lam-
421 heterotrimer. In summary, we established a sensitive and specific IB assay for the 
detection of serum IgG auto-ab against the putative major autoantigen of Lam γ-
pemphigoid. This study is of relevance in the field of serological diagnostics for 
autoimmune blistering diseases. In light of the rarity of the disorder and the lack of viable 
diagnostic assays, the study may prevent incorrect disease diagnosis and evolving 
mistreatment. Explicitly, Lam γ- 1 pemphigoid is clinically characterized by blisters 
which are normally located on the extremities and by urticated itchy plaques; this clinical 
appearance is however typical also for other diseases like BP or DH so that a reliable 
serological assay is highly needed to correctly differentiate this entity. Already 
established assays for the detection of Lam γ-1 auto-ab are not available for most centers 
since they are based on enzyme linked immunosorbent assays (ELISA) with purified Lam 
γ-1 proteins (Groth et al., 2011) or based on dermal extract IB (Zillikens et al., 1996). The 
advantage of the present IB is that a) it is based on commercially available recombinant 
proteins and b) IB is a basic diagnostic methodic which is established in every laboratory 
with routine diagnostic for autoimmune diseases. This novel IB-assay should facilitate 
the diagnosis of Lam γ-1 pemphigoid. 
 
Personal involvement in the study 
The study was presented in its preliminary form and then its final version, respectively 
during the 43nd annual meeting of the Arbeitsgemeinschaft Dermatologische Forschung 
(ADF), Vienna, Austria (2016) and the 45th Annual Meeting of the ADF, Zurich, 
Switzerland (2018). The study is published in the Journal of the European Academy of 
Dermatology and Venereology as an original research article. 
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2.2 Study II: Serological diagnostics in the detection of IgG autoantibodies against 
human collagen VII in epidermolysis bullosa acquisita: a multicenter analysis 
 
 
 
 
 
 
I.F 6.129, own contribution: 20% 
T. S wrote the manuscript, T. S, M. H, R. E and M. H designed and developed the study. 
T. S S.L-J, G. G and F. S performed the experiments, analyzed data, and prepared the 
figures. F. S recruited patientsand provided clinical information. G. D-Z, A.V. M, M. G, 
E. C, J. S. K, C. S, I. L-J, M. S, S. U, H. J, R. G, M. K, N. I, T. H provided patients 
material from their respective centers. B. G provided statistical analysis. F. S, R. E, M. H 
revised the study. All authors revised and finally approved the manuscript. 
 
EBA is a rare and life-threatening disease of the skin caused by the presence of circulating 
IgG auto-ab against human ColVII, a major compound of anchoring fibrils which are 
critical for the dermal-epidermal adhesion. Serologically, the clinical diagnosis of EBA 
is supported by the detection of IgG deposits along the DEJ by DIF, dermal binding on 
SSS of serum IgG and the detection of IgG auto-ab against ColVII by IB or ELISA. 
Nonetheless, it is often challenging to detect the IgG auto-ab against ColVII based on 
different methods with variable specificities and/or sensitivities. In an international 
retrospective multicenter study, we studied a large cohort of patients with EBA and 
evaluated the specificity and sensitivity of four different diagnostic assays for the 
detection of anti ColVII IgG auto-ab. Analyzed assays were two commercial ELISA 
systems, IIF on SSS and an in-house IB developed in our laboratory. The first ELISA kit 
(MBL, Nagoya, Japan) is based on human ColVII containing the NC1/NC2 domains 
T. Schmidt, M. Hoch, S.S Lotfi Jad, F. Solimani, G. Di Zenzo, A.V. Marzano, M. 
Goebeler, E. Cozzani, J.S. Kern, C. Sitaru, I. Lakos Jukic, M. Sardy, S. Uzun, H. 
Jedlickova, R. Gläser, M Kaneda, R. Eming, G. Göpel, N. Ishii, B. Green, T. 
Hashimoto and M. Hertl 
Br J Dermatol. 2017 Dec; 177(6): 1683-1692 
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ELISA kit, the second ELISA (Euroimmun, Lübeck, Germany) is based on the human 
ColVII-NC1 domain. The in-house IB is based on baculovirus-derived recombinant 
overlapping fragments that span the NC1 subdomain of ColVII. To assess specificity and 
sensitivity of these four different methods, we analyzed a total of 95 EBA which were 
collected in 14 centers from seven countries (Italy, Germany, Croatia, Turkey, Czech 
Republic and Japan). The diagnosis of EBA was made in the different contributing centers 
based on clinical and serological criteria, all the patientsshowed positive DIF and were 
positive in at least one of the three serological tests employed in our study (IIF on SSS, 
WB, ELISA). In addition, 100 BP sera and 50 PV sera as well as 50 sera from HC were 
included in the study. Diagnosis of BP and PV was made based on clinical phenotype, 
positive DIF of the perilesional skin and serological detection of IgG auto-ab against the 
respective autoantigens. When comparing the different assays, the highest sensitivity was 
obtained with the NC1/NC2 ELISA (97.9%, i.e. 93/95 positive sera). The sensitivity of 
the NC1 ELISA was almost comparable (89.5%, 85/95 positive sera) while WB and IIF 
on SSS showed a lower sensitivity of 85.5% and 74.4%, respectively. The findings with 
the control sera revealed a high specificity for all four tested methods. NC1/NC2 and NC1 
ELISA showed the highest specificity (99% and ~100%). In the NC1/NC2 ELISA. 1 BP 
serum reacted against human ColVII while 1 BP and 1 PV sera were reactive in the NC1 
ELISA,. WB was less specific than IIF on SSS (94% versus 99%). Furthermore, we tried 
to correlate anti-ColVII IgG auto-ab with the clinical course of 3 selected patients with 
EBA. In 2 of the 3 followed patients, reduction of IgG auto-ab in ELISA (NC1/NC2 and 
NC1 ELISA) correlated with clinical improvement, while there was no more correlation 
in the third EBA patient. This study is so far, regarding EBA studies and serological 
detection of anti IgG ColVII auto-ab, the international retrospective multicenter study 
with the largest cohort of EBA patients. We here show that the ColVII NC1/NC2 ELISA 
shows the highest sensitivity among the 4 different studied methodic and that the NC1 
ELISA also shows high levels of sensitivity. Both kits are superior to IIF on SSS and to 
WB. The slight difference in sensitivity between the two ELISA assays may be explained 
by the fact that the NC1/NC2 ELISA covers both, NH2- and COOH-terminus of the 
ColVII heterotrimer. As shown in different studies,  the majority of EBA patients have 
IgG auto-ab which target the ColVII-NC1 domain while a minority of EBA patients have 
circulating IgG auto-ab against the ColVII-NC2 domain. In our cohort, 2% of the tested 
9
 
 
EBA sera had serum IgG auto-ab that were exclusively directed against the NC2 domain 
of ColVII. 
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3. Discussion 
	
3.1 Study I: Development of a new immunoassay for the detection of autoantibodies 
against Laminin γ-1 
 
Lam γ-1 pemphigoid is a recently described  blistering disease of the skin which was 
firstly described almost simultaneously by Zillikens et al. and Chen et al. twenty years 
ago (Chen, Shimizu et al. 1996, Zillikens, Kawahara et al. 1996). Initially, the disease 
was called anti p-200 pemphigoid, since patients’ sera showed serum IgG reactivity 
against a 200 kDa protein of dermal extracts. Furthermore, DIF showed the presence of 
linear IgG deposits along the DEJ and IIF presented decoration of the DEJ by SSS, thus 
differentiating this blistering entity from BP but not from EBA or MMP (Dilling, Rose et 
al. 2007). Clinically, the disease was characterized by blisters, papules and erosions which 
often precipitate on the extremities (Meijer, Diercks et al. 2016). Interestingly, especially 
among the Japanese patients, Lam γ-1 pemphigoid is associated with Pso V. (Dilling, 
Rose et al. 2007). However, a common pathogenic link for this concomitance has not yet 
been not found. Further studies showed that the putative major autoantigen is the γ-1 
chain of laminin heterotrimers present in the skin. This finding led to the present 
denomination of the disease, Lam γ-1 pemphigoid (Dainichi, Koga et al. 2010). However, 
in vivo and ex vivo studies failed to demonstrate that IgG against Lam γ-1 is pathogenic, 
nonetheless the detection of these IgG auto-ab has been widely accepted as reliable 
serological marker for the diagnosis of Lam γ-1 pemphigoid (Vafia, Groth et al. 2012). 
Despite the availability of IB analysis with dermal extracts, and IIF on SSS, a major 
limitation is the lack of commercially available and easily reproducible assays for the 
serological detection of anti-Lam γ-1 IgG auto-ab. This limitation strongly hampered the 
acquisition of clinical, therapeutically and epidemiological information, with the 
consequence that many cases of Lam γ-1 pemphigoid, based on IIF on SSS only, were 
misdiagnosed as EBA. Different groups attempted to develop reproducible methods to 
facilitate the diagnosis of Lam γ-1 pemphigoid. Groth et al. developed an ELISA based 
on a non-commercial recombinant Lam γ-1 protein fragment, which although highly 
sensitive was only available in few specialized centers (Groth, Recke et al. 2011). 
Zillikens et al. performed IIF SSS analysis on Lam-332 and Human ColVII Knockout 
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skin models which helps to distinguish Lam γ-1 pemphigoid from EBA and MMP 
(Zillikens, Ishiko et al. 2000). This methods was conceptually based on the fact that all 
these three diseases show dermal IgG deposits by IIF on SSS of the patients sera. 
However this is a) an indirect model for detection of auto-ab b) most centers in the world 
do not dispose of knockout skin samples. Lastly, the group of Meijer et al. showed that 
DIF from perilesional skin of Lam γ-1 pemphigoid patients showed a peculiar serrated 
pattern (n-serrated) due to the IgG deposits at the DEJ, which helps to differentiate it from 
EBA (u-serrated IgG deposits) (Meijer, Diercks et al. 2016, Meijer, Atefi et al. 2017). 
Nonetheless also these methods are not widely available and need intensive training of 
the users beforehand. In our study, we aimed to develop an easy-to-reproduce 
immunoblot which can be performed in every laboratory with basic lab skills. This IB is 
based on two laminin heterotrimers, Lam-421 and Lam-111, and on a recombinant, 
purified, isolated Lam γ-1 chain. All these three proteins are commercially available. This 
IB also showed to be highly specific: Based on a total of 41 control era, the overall 
observed specificity was of 87.8%. In conclusion, blistering diseases crucially rely on the 
development and presence of specific and sensitive immunoassays for the detection of 
circulating auto-ab. In Summary we developed an easy-to-perform and reliable 
immunoserological assay which could be theoretically implemented worldwide to 
establish the diagnosis of Lam γ-1 pemphigoid. 
 
3.2 Study II: Analysis of serological diagnostic methods for the detection of IgG 
autoantibodies against human collagen VII in epidermolysis bullosa acquisita 
 
EBA is a severe, rare autoimmune bullous disease of the skin and is serologically 
characterized by the presence of IgG auto-ab directed against ColVII, the major 
component of anchoring fibrils (Kim and Kim 2013). By IIF the diagnosis of EBA is hard 
to establish as EBA sera, similarly to MMP and Lam γ-1 pemphigoid sera, show l IIF 
reactivity with the dermal side of SSS.  Clinically, EBA presents with a wide spectrum of 
skin manifestations and may be hard to be distinguished from BP, dystrophic EB and 
LAD. Nonetheless, two different types of EBA have been described: a mechanobullous 
type with extensive blistzering and scarring at the acral sides and mucous membranes and 
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an inflammatory type which is associated with local inflammation, complement 
activation and neutrophil recruitment (Kim and Kim 2013). In general, EBA patients 
present severe and prolonged skin fragility which is reflected by the presence of tense 
blisters, typically prominent on mechanically stressed skin areas and mucous membranes, 
with oral, conjunctival or genital lesions. Blisters often present with secondary milia 
formation and heal with scarring (Kim and Kim 2013).  EBA is a potentially lethal disease 
and often shows a chronic relapsing course. Present therapeutic options are widely based 
on corticosteroids, often combined with adjuvant immunosuppressive drugs such as 
azathioprine, mycophenolate mofetil or cyclophosphamide (Gurcan and Ahmed 2011). 
In addition, immunoadsorption, intravenous immunoglobulins or anti-CD20 monoclonal 
antibody (rituximab) have shown positive effects in refractory cases (Schmidt, Benoit et 
al. 2006, Kim, Lee et al. 2012). Given the severity of EBA, it is crucial to develop highly 
specific and sensitive tools to establish the diagnosis based of EBA based on serological 
analysis. In this international multicentric retrospective study, we investigated a large 
cohort of sera coming from different European countries and Japan. The scope of the 
study was to evaluate the diagnostic power of four different methods for the detection of 
anti ColVII IgG auto-ab. The study included 95 EBA sera which have been tested by DIF, 
IIF, WB and with two different ELISA kits, respectively a ColVII NC1/NC2 ELISA 
(MBL, Nagoya, Japan) and a ColVII-NC1 ELISA (Euroimmun, Lübeck, Germany). 
Furthermore, 200 control sera were included in this study, 100 sera from BP patients, 50 
PV and 50 HC. Our results show that the highest sensitivity was obtained with the 
NC1/NC2 ELISA (97.9%), followed by the NC1 ELISA (89.5%). WB analysis had a 
sensitivity of 85.3%, while IIF analysis showed the lowest sensitivity among these four 
techniques (85.3%). Similarly, both ELISA were highly specific (~100), IIF analysis also 
delivered high specificity (99%) while WB analysis showed the lowest specificity (94%) 
Of note, sensitivity of the NC1/NC2 ELISA was importantly higher than the ELISA 
against only the NC1 epitope. This finding confirms that, although most of the tested EBA 
sera contained IgG auto-ab against the NC1 epitope (Lapiere, Woodley et al. 1993), a 
significant number of sera also reacted with the less frequently targeted NC2 subdomain 
of ColVII (Fukumoto, Umekawa et al. 2004, Ishii, Yoshida et al. 2004). In conclusion, 
we here show that two commercially available ELISA assays (ColVII-NC1/NC2 ELISA 
13
 
 
and ColVII-NC1 ELISA) provide the highest specificity and sensitivity and should be 
used in first place for making the diagnosis of EBA. 
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5. Summary 
 
Pemphigoid diseases encompass a heterogeneous group of subepidermal autoimmune 
bullous diseases of the skin and mucosa. These disorders are characterized by 
autoantibodies that target distinct structural proteins of the basement membrane zone 
which are crucial for the integrity of the skin. Targeting of these proteins leads to skin 
fragility, detachment of the epidermis and eventually formation of blisters and skin 
inflammation. The clinical presentation of the pemphigoids is heterogeneous, the 
subtypes are divided by clinical symptoms, target antigens and response to treatment. A 
crucial step for the proper classification is the serological detection of the autoantigens 
directed against distinct components of the dermal epidermal junction. Thus, it is crucial 
to develop reliable and reproducible diagnostic methods which help clinicians to 
differentiate between different entities and therefore to select the best treatment. This 
thesis is focused on Laminin γ-1 pemphigoid and epidermolysis bullosa acquisita, the 
study of their clinical appearance and the development and validation of serological 
assays to correctly diagnose these two entities. Both autoimmune blistering diseases are 
rare and often hard to diagnose with standard serological assays. In the first study 
presented in this thesis, I discuss the development of an immunoblot assay for the 
detection of autoantibodies against Laminin γ-1. Laminin γ-1 pemphigoid is a novel 
subepidermal blistering disease which has been first described in 1996. Since then, 
different immune serological methods for the detection of circulating autoantibodies have 
been described, however these are often not reproducible for most of the centers 
worldwide, since often advanced lab skills are required. In our study, we present a novel 
immunoblot assay based on three commercially available Laminin γ-1 recombinants, 
which can be reproduced in almost every laboratory with basic skills. In the second study, 
we thought to serologically identify for the best immunoassay for the detection of serum 
IgG autoantibodies against anti-human collagen VII in patients with epidermolysis 
bullosa acquisita. Epidermolysis bullosa acquisita is a severe blistering diseases 
characterized by circulating IgG autoantibodies targeting human collagen VII. In this 
study, four different diagnostic assays (immunoblot, indirect immunofluorescence with 
saline split human skin and 2 enzyme linked immunosorbent assays) have been tested and 
compared with regard to their sensitivity and specificity in a large cohort of epidermolysis 
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bullosa acquisita sera (n=95). In summary, our study showed that enzyme linked 
immunosorbent assays based on recombinant human collagen VII NC1-NC2 or collagen 
VII-NC1 proteins provide the highest sensitivity and specificity for the detection of anti-
collagen VII IgG and should be preferred to immunoblot analysis or indirect 
immunofluorescence on saline split human skin in making the diagnosis of epidermolysis 
bullosa acquisita.  
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6. Zusammenfassung 
 
Die Pemphigoide umfassen eine heterogene Gruppe von subepidermalen autoimmun 
bullösen Erkrankungen der Haut und der Schleimhaut. Diese Erkrankungen sind durch 
Autoantikörper gekennzeichnet, die auf bestimmte Strukturproteine der 
Basalmembranzone abzielen, die für die Integrität der Haut entscheidend sind. Ein 
gezieltes Anzielen dieser Proteine führt zu Brüchigkeit der Haut, Ablösung der Epidermis 
und schließlich zur Bildung von Blasen und Hautentzündungen. Das klinische 
Erscheinungsbild der Pemphigoide ist heterogen, die Subtypen sind nach klinischen 
Symptomen, Zielantigenen und Ansprechen auf die Behandlung unterteilt. Ein 
entscheidender Schritt für die korrekte Klassifizierung ist der serologische Nachweis von 
Autoantikörpern gegen bestimmte Komponenten der dermal- epidermalen 
Junktionszone. Daher ist es wichtig, zuverlässige und reproduzierbare Diagnoseverfahren 
zu entwickeln, die den Ärzten dabei helfen, zwischen verschiedenen Entitäten zu 
unterscheiden und somit die beste Behandlung auszuwählen. Diese Dissertation 
konzentriert sich auf Laminin-γ-1-Pemphigoid und Epidermolysis bullosa acquisita, die 
Untersuchung ihres klinischen Erscheinungsbildes und die Entwicklung und Validierung 
serologischer Tests zur korrekten Diagnose dieser beiden Entitäten. Beide 
Autoimmunkrankheiten sind selten und mit serologischen Standardassays oft schwer zu 
diagnostizieren. In der ersten Studie, die in dieser Dissertation vorgestellt wurde, 
diskutiere ich die Entwicklung eines Immunoblot-Assays zum Nachweis von 
Autoantikörpern gegen Laminin γ-1. Laminin-γ-1-Pemphigoid ist eine neue 
blasenbildende Erkrankung der Pemphigoidgruppe, die erstmals 1996 beschrieben 
wurde. Seitdem wurden verschiedene Methoden zum Nachweis zirkulierender 
Autoantikörper nachgewiesen, die jedoch für die meisten Zentren weltweit häufig nicht 
reproduzierbar sind, da fortgeschrittene Labortechniken erforderlich sind. In unserer 
Studie stellen wir einen neuartigen Immunoblot-Assay vor, der auf kommerziell 
erhältlichen rekombinanten Proteinen des Laminin γ-1 basiert und in fast jedem Labor 
mit grundlegenden Kenntnissen reproduziert werden kann. In der zweiten Studie 
untersuchen wir, den besten Immunoassay zum Nachweis von Autoantikörpern gegen 
Anti-Human-Kollagen VII bei Patienten mit Epidermolysis bullosa acquisita serologisch 
zu identifizieren. Epidermolysis bullosa acquisita ist eine schwere blasenbildende 
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Autoimmunerkrankung, die durch zirkulierende IgG-Autoantikörper gegen humanes 
Kollagen VII gekennzeichnet ist. In dieser Arbeit wurden vier verschiedene diagnostische 
Assays (Immnoblot, indirekte Immunfluoreszenz mit menschlicher Kochsalz-Spalthaut 
und zwei ELISA) getestet und hinsichtlich ihrer Sensitivität und Spezifität in einer großen 
Kohorte von Epidermolysis bullosa acquisita-Seren verglichen (n = 95). 
Zusammenfassend hat unsere Studie gezeigt, dass ein ELISA, der auf rekombinanter 
humaner Kollagen-VII-NC1-NC2-Domäne oder Kollagen-VII-NC1-Domäne basiert, die 
höchste Empfindlichkeit und Spezifität für den Nachweis von Anti-Kollagen-VII IgG-
Antikörper bietet. 
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Abstract
Background Anti-laminin-c1 (lam-c1) pemphigoid, a recently described immunobullous disorder sharing immune sero-
logical features of bullous pemphigoid and epidermolysis bullosa acquisita (EBA), is characterized by the detection of
serum IgG autoantibodies against the lam-c1 chain, a 200 kDa heterotrimeric component of the dermal-epidermal junc-
tion (DEJ).
Objective The aim of the study was to develop an easy-to-perform and reliable assay for the serological detection of
anti-lam-c1 IgG autoantibodies. The clinical appearance alone is not sufficient to establish diagnosis of anti-lam-c1 pem-
phigoid and rather requires immune serological evidence of (i) IgG reactivity against the dermal portion of salt-split
human skin; (ii) exclusion of IgG against other components of the DEJ; and (iii) IgG reactivity with a 200 kDa protein of
dermal extracts by immunoblot analysis (IB).
Methods The sera of 55 patients with anti-lam-c1 pemphigoid were tested by IB with two recombinant heterotrimers, lami-
nin 111 (lam-111) and laminin 421 (lam-421), as well as with a recombinant lam-c1 chain monomer. Additionally, a total of 41
control sera from patients with EBA (n = 15), psoriasis vulgaris (PV; n = 14), and healthy controls (HC; n = 12) were tested.
Results Immunoblot analysis revealed a positive reactivity with lam-111 and/or lam-421 in 46/55 (84%) of anti-lam-c1
pemphigoid sera. Moreover, 8/9 of the initially non-reactive sera were positive with the lam-c1 monomer, leading to an
overall sensitivity of 98.2%. Analyses of 41 control sera with the three lam-c1 recombinants led to a specificity of 88%.
Specifically, 3/15 EBA sera, 1/14 PV serum and 1/12 HC serum reacted with the lam-c1 monomer while only the 3 EBA
sera reacted with lam-421.
Conclusions Here we show a novel two-step IB assay using the two recombinant laminin trimers and lam-c1 chain
monomer for the detection of anti-lam-c1 serum IgG with high sensitivity and specificity. This assay will facilitate the
diagnosis and further characterization of this disease.
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Introduction
Twenty years ago, anti-laminin c1 (lam-c1) pemphigoid which
is also known as anti-p200 pemphigoid, was independently
described by Zillikens et al. and by Chen et al. as a novel
autoimmune bullous skin disorder with IgG autoantibodies
against the dermal-epidermal junction (DEJ) which did not tar-
get any of the known autoantigens of the DEJ including bullous
pemphigoid (BP) 180, BP230, laminin-332 (lam-332), and type
VII collagen (ColVII).1,2 The disorder was characterized clini-
cally by BP-like inflammatory phenotype and, immune serologi-
cally, by serum IgG against a 200 kDa protein of dermal extracts
leading to the initial denomination of anti-p-200 pemphigoid.3
Further studies showed that the non-collagenous p-200 protein
was a new autoantigen different from other known autoantigens
and was synthesized by keratinocytes and fibroblasts.4–6 Finally,
the p-200 protein was identified as the c-1 chain of laminin lead-
ing to the later denomination as anti-lam-c1 pemphigoid.7,8
Lam-c-1 is a ubiquitous protein present in almost every tissue
and a component of multiple laminin heterotrimers.9 In the
†Shared authorship.
‡Shared authorship.
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skin, the protein is located in the DEJ within the lower lamina
lucida.10,11
Clinically, anti- lam-c1 pemphigoid mostly resembles BP with
tense blisters, urticated papules and plaques and pronounced
pruritus. The blisters often exhibit an acral distribution (Fig. 1).
In general, patients respond well to topical and systemic
immunosuppressive treatment with a response pattern similar to
BP.3,8 As sera of anti-lam-c1 pemphigoid patients show a reac-
tivity pattern by IIF similarly to EBA, i.e. IgG reactivity within
the dermal side of salt-split human skin, these patients were
occasionally misdiagnosed as inflammatory type of EBA.12 Note-
worthy, anti-lam-c1 pemphigoid has been frequently described
in association with psoriasis vulgaris predominantly in the Japa-
nese population.2,13 However, the etiopathogenetic links
between the two disorders are not yet well-understood.14,15 Fur-
thermore, laminins are also known autoantigens in other inflam-
matory diseases such as lupus erythematosus and vasculitis.16,17
Almost 100 cases of anti-lam-c1 pemphigoid have been pub-
lished so far,18–20 and, except one all reported cases were IgG
mediated.21 Due to its rarity and limited availability of specific
diagnostic methods, anti-lam-c1 pemphigoid is largely under-
diagnosed and mistreated as the inflammatory type of EBA. At
present, the diagnosis of anti-lam-c1 pemphigoid is based on:
(i) direct immunofluorescence (DIF) of perilesional skin; (ii)
indirect immunofluorescence microscopy (IIF) with salt-split
human skin (SSS), and (iii) immunoblot analysis (IB) with
dermal extracts (Fig. 3).12 Histopathology of the skin reveals
subepidermal loss of adhesion with a superficial inflammatory
infiltrate containing eosinophils and/or neutrophils which
resembles BP or linear IgA bullous dermatosis.22 Immune sero-
logically, DIF shows linear deposits of IgG and C3 along the DEJ
while IIF shows dermal IgG binding to SSS which discriminates
this disorder from BP. Further biochemical and genetic
approaches revealed that the autoantigen is a non-collagenous
glycoprotein which is synthesized by keratinocytes and dermal
fibroblasts.2 Recently, Dainichi et al.23 identified the lam-c1
chain as the target antigen of the majority of the patients’ sera.
Even though ex vivo and in vivo studies have failed to show
direct pathogenicity of anti-lam-c1 IgG autoantibodies,24–26 the
serological detection of anti-lam-c1 IgG still remains the gold
standard for establishing the diagnosis of anti-lam-c1 pem-
phigoid. At present, IB analysis with purified lam-c1 or dermal
extract represents the most reliable method for the serological
detection of lam-c1 IgG autoantibodies. This method is, how-
ever, only performed in a few specialized centres and largely
depends on the quality of the employed protein preparations.
In this study, we present an easy-to-perform and highly sensi-
tive IB assay for the serological detection of anti-lam-c1 IgG,
which is based on three commercially available recombinant
proteins containing the lam-c1 chain. This novel IB assay should
enable many laboratories to correctly diagnose and subsequently
properly treat anti-lam-c1 pemphigoid.
Figure 1 Clinical, histopathological and immunofluorescence microscopic findings in anti-laminin c1 pemphigoid. (a–d) Excoriated
pruritic papules (a), tense blisters (b), urticated papules and plaques (c), and concomitant plantar psoriasis (d) in a patient with anti-laminin
c-1 pemphigoid. (e) Subepidermal loss of adhesion with superficial dermal inflammatory infiltrate (e). (f,g) IgG deposits along the dermal-
epidermal junction by direct immunofluorescence (f), and serum IgG autoantibodies labelling the dermal side of salt-split human skin (g).
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Materials and methods
Patients
The study included a total of 49 Japanese and 6 European
patients with anti-lam- c1 pemphigoid who fulfilled the follow-
ing criteria: (i) presence of blisters, urticarial lesions and pru-
ritic, excoriated papules; (ii) linear IgG deposits along the DEJ
by DIF of perilesional skin; (iii) serum IgG reactivity with the
dermal side of human SSS by IIF; and (iv) absence of serum IgG
against other components of the DEJ (BP180, BP230, ColVII
and Lam-332). In addition, all the 49 Japanese sera showed IgG
reactivity against a 200 kDa protein of dermal extracts by IB.
The 55 anti-lam-c1 pemphigoid patients include 33 were male
and 13 female, while the genders for 9 patients were retrospec-
tively not identifiable gender. The mean age of the patients at
disease onset was 63.6 years. Sera from patients with psoriasis
vulgaris (n = 14), EBA (n = 15), and healthy individuals
(n = 12) served as controls. The protocol of the present study
was approved by the Ethics Committee of the Medical Faculty of
Philipps University Marburg, Germany.
Indirect immunofluorescence microscopy with salt-split
normal human skin
Preparation and evaluation of immunofluorescence microscopy
on salt-split human skin was performed as previously
described.27
Exclusion of other circulating autoantibodies
IgG serum autoantibodies against BP180, BP230 and ColVII
were excluded using commercially available ELISA (Euroim-
mun, L€ubeck, Germany); according to the manufacturers’ proto-
col.27
Presence of autoantibodies against laminin 332 were excluded
by ELISA using native human laminin 332 as previously
described.28
Immunoblot analysis with recombinant laminin proteins
Recombinant lam-111 and recombinant lam-421 were pur-
chased from Biolamina, Sundbyberg, Sweden. Purified lam-c1
and rabbit polyclonal anti-lam-c1 antibody were purchased
from OriGene, Rockville, MD, USA. SDS/PAGE and IB was per-
formed as follows: according to their molecular weight, proteins
were separated by SDS-Page in a discontinuous buffer system
using the Multigel system (Biometra, Gottingen, Germany). The
polyacrylamide gel consists of a lower separation gel at a concen-
tration of 7.5% and the upper stacking gel containing 30% acry-
lamide. The proteins were denatured by boiling (for 5 min at
95°C) and 8 lg of lam-111, lam-421 and 2.5 lg of lam-c1-chain
was applied on the chamber. After separation, the proteins were
transferred to a nitrocellulose membrane (Peqlab Biotechnolo-
gie, Erlangen, Germany) at 300 mA, 150 V for 1.5 h. Thereafter,
the membrane was washed with TBS and blocked with TBS/10%
milk powder. Afterwards, the membranes were incubated with
patients’ sera diluted at 1 : 200 in PBST (1 9 PBS + 0.1%
Tween-20) overnight and incubated by 4°C under shaking con-
ditions. Positive controls included a lam-c1-reactive human
serum (1 : 200) and a rabbit anti-lam-c1 primary antibody
(OriGene), healthy control (HC) sera served as a negative con-
trol. IgG binding was visualized by a digital chemoluminescence
reader (PEQLAB, Erlangen, Germany).
Results
Sensitivity of immunoblot analysis with recombinants
laminins
The studied cohort of anti-lam-c1 pemphigoid patients’ sera
was characterized by IgG reactivity with the dermal portion of
human SSS, and a lack of IgG reactivity with well-known
autoantigens of the DEJ including BP180, BP230, lam-332, and
ColVII. Moreover, 49/55 tested sera were previously shown to
display IgG reactivity against a 200 kDa protein of human der-
mal extracts. In a first step, all the sera were tested with two het-
erotrimers containing the lam-c1 chain, i.e. lam-111 and lam-
421. As shown in Fig. 2 Table 1, 46/55 sera showed IgG reactiv-
ity to either lam-111 and/or lam-421 resulting in a sensitivity of
83.6%. In a second step, all the nine sera which were neither
reactive with lam-111 nor with lam-421 were tested by IB with
purified lam-c1 monomer. A total of 8/9 sera were IgG reactive
with the lam-c1 chain (Fig. 2 and Table 1).
To prove that the portion of lam-421 and lam-111 which
reacted with the lam-c1 sera by IB analysis was indeed the c1
chain of laminin, we tested 10 sera reactive with both, lam-111
and lam-421 with lam-c1 monomer. In fact, all these sera
showed IgG reactivity against the 200 kDa protein (data not
shown). Only one single patient with serum IgG reactivity
against the dermal side of human SSS (anti-collagen VII IgG
negative) did not react with any of the laminins and this serum
was eventually considered as negative (1.8%; Table 1). Overall,
combining IB analysis with the heterotrimers, lam-111 and lam-
421, and the monomeric lam-c1 chain (step 1 and 2), resulted in
a final sensitivity of 98.2% (54/55 sera positive).
Remarkably, the recombinant lam-c1 of the present IB had a
molecular weight close to 250 kDa (Fig. 2). This largely depends
on differential NH2-linked glycosylation leading to a variable
molecular weight of lam-c1 ranging from 200 to 250 kDa.29
Specificity of immunoblot with recombinants laminins
This study included a total of 41 control sera, i.e. 12 HC, 14 sera
from patients with psoriasis (as anti-lam-c1 pemphigoid is clini-
cally associated with psoriasis) and 15 EBA sera (as EBA sera also
show IgG reactivity with the dermal part of human SSS; Fig. 2
and Table 2). Upon IB analysis with lam-111 and lam-421, 3
EBA sera showed positive IgG reactivity. Of note, 5 control sera
showed IgG reactivity against the lam-c1 monomer, i.e.1 HC
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serum, 1 PV serum and 3 EBA sera. Three EBA sera showed
additional IgG reactivity against lam-421. Overall, 5/41 control
sera showed IgG reactivity against at least one of the three lami-
nins leading to a specificity of 87.8% (Table 2).
Figure 3 shows the diagnostic algorithm for various subepi-
dermal autoimmune bullous diseases with dermal IgG deposition
in human SSS including the novel methods for anti-laminin-c1
pemphigoid established in this study.
Discussion
Anti-lam-c1 (anti-p200) pemphigoid is a peculiar pemphigoid
variant; i.e., most patients with this disease present clinically
Figure 2 Detection of laminin-c1 IgG autoantibodies with three recombinant laminins by immunoblot analysis. (a) Five representative
anti-laminin (lam)-c1 pemphigoid sera (P1–P5) with three different recombinant laminins: the heterotrimers, lam-111 and lam-421, and the
lam-c1 chain monomer. The denatured lam-c1 chain is visible at a molecular weight of about 250 kDa. (b) The IgG reactivity of five healthy
control (HC), pemphigus vulgaris (PV) and epidermolysis bullosa acquisita (EBA) sera with recombinant lam-c1 proteins.
Table 1 Sensitivity of immunoblot analysis with three recombi-
nant laminins containing the lam-c1 chain
Sera from patients with
anti-lam-c1-pemphigoid
lam-111 lam-421 lam-c1 Sensitivity
(%)
Step 1 – lam-111 and
lam-421 heterotrimers
36/55 positive 65.4
44/55 positive 80.0
46/55 positive 83.6
Step 2 – lam-c1 monomer
8/9+ 88.8
Total 54/55 positive 98.2
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with a BP-like inflammatory phenotype but shows serologically
EBA-like reactivity by IIF using SSS.1 Due to its rarity and the
lack of routinely used diagnostic procedures, the disorder is fre-
quently under-diagnosed.30 Clinically, anti-lamc-1 pemphigoid
is defined by urticated plaques and tense blisters which are char-
acteristically located on the extremities and do not present signs
of scarring or milia formation. However, the clinical features
may show a wide variability including those of BP, EBA, and
dermatitis herpetiformis.22,31 The recent identification of the
lam-c1 chain as target autoantigen of the majority of anti-lam-c1
(anti-p200) pemphigoid sera has opened an avenue to more
precisely diagnose this rare pemphigoid variant 23
Table 2 Specificity of immunoblot analysis with three recombinant laminins containing the laminin-c1 chain
Control group lam-111 lam-421 lam-c1 Total Specificity (%)
Healthy controls 0/12+ 0/12+ 1/10 1/12+ 91.7
Epidermolysis bullosa acquisita 3/15+ 3/15+ 3/15+ 3/15+ 80.0
Psoriasis vulgaris 0/14+ 0/14+ 1/14+ 1/14+ 92.9
Total 3/41+ 3/41+ 5/39+ 5/41+ 87.8
IB with 
lam-γ1 monomer
IB with human dermal 
extracts
(Zilikens et al, Chen et al.)
ELISA with lam-γ1
(Groth et al., 2011)
IB with lam-111, lam-421
(current study) 
α-lam-γ1
   
IgG
Anti-Lam-γ1 pemphigoid
ELISA
IB 
(with colVII 
recombinant fragment)
α-ColVII
   
IgG
EBA
IB
(ECM from cultured 
keratinocytes)
Immuno-
precipitation
(Laminin-332)
αLam332
  
IgG
MMP
Autoimmune blistering disease
 (subepidermal loss of adhesion)
DIF: Linear deposits of IgG ± at DEJ
IIF (salt-split human skin, SSS):
IgG reactivity with dermal side of SSS
or
or
or or
Figure 3 Diagnostic algorithm for establishing the diagnosis of anti-laminin-c1 pemphigoid. Shown is an algorithm to distinguish subepi-
dermal autoimmune blistering diseases. The clinical appearance and presence of IgG deposits along the dermal–epidermal junction (DEJ)
or IgG reactivity with the dermal side of the salt-split skin (SSS) is not sufficient to establish proper diagnosis of a distinct subepidermal
blistering dermatosis. Detection of serum IgG autoantibodies is needed to distinguish between anti-lam-c1 pemphigoid, epidermolysis
bullosa acquisita (EBA) and mucous membrane pemphigoid (MMP). Immunoblot analysis (IB) with commercially available laminin (lam)-
111 and lam-421 strongly facilitates the detection of serum autoantibodies in anti-lam-c1 pemphigoid. In case of lack of serum IgG reac-
tivity with the lam-c1 heterotrimers, IB can be performed with the lam-c1 monomer. DIF, direct immunofluorescence; ECM, extracellular
matrix; ELISA, enzyme-linked immunoassorbent assay; IB, immunoblot, IIF, indirect immunofluorescence.
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We here established a highly sensitive and specific IB assay for
the detection of serum IgG autoantibodies against lam-c1, the
putative major autoantigen of anti-lam-c1/anti-p200 pem-
phigoid. The present IB assay is based on three recombinant
proteins, i.e. the heterotrimers, lam-111 and lam-421, and the
lam-c1 monomer. The great advantage of the newly developed
immunoassay is the accessibility of the employed lam-c1 recom-
binants which are commercially available to many laboratories
worldwide. The proposed two-step IB analysis with two lam-c1
heterotrimers, i.e. lam-111 and lam-421, and a lam-c1 monomer
in case of no reactivity to the heterotrimers, allows the in vitro
detection of lam-c1-specific IgG autoantibodies at a high sensi-
tivity and specificity. Using the proposed two-step IB assay, a
total of 54/55 sera from anti-lam-c1 pemphigoid patients were
found to be positive (98.2%), while 46 sera were already found
to be lam-c1-reactive at the first step IB with the two lam-c1
heterotrimers (83.6%; Table 1). Using 41 control sera, we
observed a specificity of 87.8% of this two-step IB assay
(Table 2). In detail, 3 EBA sera reacted by IB with all the lam-c1
recombinant proteins while 1 HC and 1 PV serum reacted with
the lam-c1 monomer only. In the case of the 3 EBA sera, chronic
skin inflammation at the DEJ may have led, e.g. through epitope
spreading, to the development of autoantibodies against lam-c1.
However, this assumption needs to be verified prospectively in a
cohort of EBA patients.
At present, the diagnosis of anti-lam-c1 pemphigoid is
based on a mix of clinical, histopathological and immune
serological findings.32 Although the significance of lam-c1-specific
IgG autoantibodies is still unresolved, as ex vivo and in vivo
models failed to show pathogenic properties of these autoanti-
bodies,24,25 their detection in the patients’ sera is a diagnostic
hallmark in establishing diagnosis of anti-lam-c1 pemphigoid.
Previously, detection of IgG serum autoantibodies against a
200 kDa protein of dermal extracts was the standard immune
serological procedure which is highly reliable but only
available in a few specialized centres.1,7 Recently, Groth et al.33
developed an ELISA assay utilizing a recombinant lam-c1
fragment, which is also restricted to a few centres with the
capacity to produce the recombinant protein. Zillikens et al.34
developed an assay based on IIF knockout analysis which
allowed exclusion of EBA and anti-lam332-type mucous
membrane pemphigoid. Lastly, Meijer et al.12,32 analyzed the
serrated pattern profile of perilesional skin of anti-lam-c1
pemphigoid patients, and found that, in contrast to the u-serrated
pattern for EBA sera, anti-lam-c1 pemphigoid presented with
a n-serrated pattern, characteristic of BP. The lack of easily
reproducible techniques strongly limits the diagnosis of anti-
lam-c1 pemphigoid and leads to an under-recognition of this
pemphigoid variant.
Epidemiological data are poor and based on small
cohorts.12,30 In the reported studies, patients with anti-lam-c1
pemphigoid seem to be younger than BP patients with an age of
disease onset varying from 60 to 65 years.12 In our cohort, the
mean age of onset was 63.6 years, which confirms previous data
suggesting a slight earlier onset of the disease. Furthermore, our
study cohort showed male predominance.
In conclusion, the lack of easily reproducible assays for the
detection of IgG autoantibodies against lam-c1 represents a
major restriction for establishing the diagnosis of anti-lam-c1
pemphigoid, a rare but significant pemphigoid variant. We here
developed a reliable serological IB assay for the detection of
serum autoantibodies based on the use of commercially available
recombinant proteins, i.e., heterotrimeric lam-111 and lam-421
proteins and a monomeric lam-c1 chain. This novel, highly sen-
sitive and widely accessible two-step IB assay will help to better
diagnose anti-lam-c1 pemphigoid, a currently under recognized
pemphigoid variant.
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Summary
Background Epidermolysis bullosa acquisita (EBA) is a rare, potentially devastating
autoimmune disease of the skin. IgG autoantibodies directed against type VII col-
lagen (Col7), the major component of anchoring fibrils, induce skin fragility
leading to cutaneous and mucocutaneous blister formation, which is mostly of a
scarring phenotype. Thus, powerful and reproducible diagnostic assays are critical
to establish the diagnosis of EBA early to avoid irreversible sequelae.
Objectives The present international, retrospective multicentre study included a
large cohort of patients with EBA and evaluated the diagnostic power of four dif-
ferent diagnostic assays for the detection of anti-Col7 IgG autoantibodies.
Methods Overall, 95 EBA sera and 200 control sera consisting of 100 bullous pem-
phigoid sera, 50 pemphigus vulgaris sera and 50 sera of healthy controls were
tested for anti-Col7 IgG autoantibodies using indirect immunofluorescence (IIF),
two commercial enzyme-linked immunosorbent assay (ELISA) systems and Wes-
tern blot (WB) analysis. EBA sera were taken from patients with positive direct
immunofluorescence and IgG reactivity in at least one of the immunoserological
assays (IIF, ELISA, WB).
Results A Col7-NC1/NC2 ELISA (MBL, Nagoya, Japan) showed the highest sensi-
tivity (97!9%), followed by a Col7-NC1 ELISA (Euroimmun, L€ubeck, Germany)
(89!5%), WB with Col7-NC1 (85!3%), and IIF on saline-split human skin
(74!7%). The specificities of both ELISA systems were comparable (NC1 98!7%,
NC1/NC2 99!3%). Furthermore, WB was more sensitive than IIF, which was
more specific.
Conclusions The two commercially available ELISA systems allow for a highly sensi-
tive and specific diagnosis of EBA. The sensitivity of the Col7-NC1/NC2 ELISA is
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significantly higher compared with the ELISA based on the Col7-NC1 domain
only.
What’s already known about this topic?
• Diagnosis of epidermolysis bullosa acquisita (EBA) is based on positive direct
immunofluorescence (DIF) and immunoserological detection of IgG autoantibodies
against type VII collagen (Col7).
• Skin-bound IgG autoantibodies can be detected at a high sensitivity and specificity
by immunoelectron microscopy and serration pattern analysis of DIF.
• Indirect immunofluorescence, enzyme-linked immunosorbent assay (ELISA) and
Western blotting are the most commonly used methods for the serological detec-
tion of anti-Col7 IgG autoantibodies.
What does this study add?
• This study contains the largest cohort of patients with EBA in the context of studies
dealing with the serological detection of anti-Col7 IgG autoantibodies.
• The two commercially available ELISA systems showed the highest sensitivity and
highest rates of specificity.
• The results demonstrate that the sensitivity of the Col7-NC1/NC2 domain ELISA is
significantly higher compared with the ELISA based on the Col7-NC1 domain only.
Epidermolysis bullosa acquisita (EBA) is a severe, acquired
autoimmune bullous disease with a prevalence of approxi-
mately one to five cases per million people.1 It is characterized
by the presence of IgG autoantibodies directed against type
VII collagen (Col7), a major component of anchoring fibrils,
which are responsible for the anchorage of the epidermal basal
membrane zone (BMZ) to the dermis.2–4 Binding of anti-Col7
IgG leads to a destabilization of the BMZ resulting in severe
skin fragility and subsequent subepidermal loss of adhesion.
Thereby, blisters are induced by a direct antibody impact
(mechanobullous type) or by an antibody-induced local
inflammation cascade including complement activation and
neutrophil recruitment (inflammatory type).
Epidermolysis bullosa acquisita was first described by Elliot
in 1895 and occurs independently of age, sex or ethnic
group.5 It is genetically associated with the human leucocyte
antigen (HLA) major histocompatibility class (MHC) II allele
HLA-DR2, which is also associated with other autoimmune
diseases.6–8 Clinically, EBA presents with cutaneous and muco-
cutaneous blisters and erosions, which often lead to a scarring
phenotype with milia formation and nail loss.
Owing to the wide spectrum of clinical manifestations of
EBA, various differential diagnoses including dystrophic epi-
dermolysis bullosa, bullous pemphigoid (BP), linear IgA der-
matosis and pemphigus vulgaris (PV), have to be considered
(Fig. 1). The diagnosis of EBA is based on the clinical pheno-
type in combination with direct immunofluorescence (DIF),
indirect immunofluorescence (IIF) on saline-split skin (SSS)
and the serological detection of anti-Col7 IgG autoantibodies.9
The present international retrospective multicentre study
compared the specificity and sensitivity of four different stan-
dardized serological assays for the detection of anti-Col7 IgG,
including two commercial enzyme-linked immunosorbent
assay (ELISA) systems, IIF on SSS and Western blotting (WB).
The results demonstrate that the ELISA systems delivered the
highest sensitivity, followed by IIF and WB. Of note, a Col7-
NC1/NC2 ELISA showed a significantly higher sensitivity than
a Col7-NC1 ELISA, even though their specificities were com-
parable. Furthermore, WB was more sensitive than IIF while
IIF showed a higher level of specificity than WB.
Materials and methods
Patient and control sera
A total of 95 EBA sera were analysed in this retrospective mul-
ticentre study. For each serum the centres filled out a study
form that included information on the methods used for the
immunoserological assessment of EBA (Table S1; see Support-
ing Information), clinical phenotype and treatment. The spec-
trum of diagnostics included clinical appearance, histology,
DIF of perilesional skin, IIF (SSS–IgG reactivity with the der-
mal portion), ELISA and WB analysis. All of the sera were
from patients with EBA with positive DIF and were positive in
at least one serological test (IIF/ELISA/WB). A total of 98% of
the tested EBA sera were initially tested by IIF (SSS and/or
monkey oesophagus) in the contributing centres.
Overall, 3% of the sera were tested by ELISA only. Owing
to the limited relevance of monkey oesophagus analysis, the
monkey oesophagus data were deleted. Thus, 91 of 95 EBA
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sera (96%) were initially tested by SSS in the contributing
centres. Of these 91 sera, three (3%) sera tested negative. As
shown in Table S1 (see Supporting Information), 97% of the
SSS-tested EBA sera were initially positive, whereas only 75%
were positive upon reanalysis in the present study (including
four samples that were not initially tested in the respective
centres). The observed difference in the sensitivity of SSS anal-
ysis of the EBA sera may be related to factors dependent on
the time period between initial analysis at the contributing
centre and our analysis, such as storage of the sera. This
became apparent when the study showed that SSS was the
method of lowest sensitivity compared with WB and ELISA. In
contrast, all the EBA sera that initially tested positive by ELISA
in the contributing centres remained positive upon reanalysis
in our laboratory. It is noteworthy that all of the six EBA sera
that were initially tested by SSS in only the contributing cen-
tres were also positive by SSS upon reanalysis in our labora-
tory.
Overall, 41% of the sera were collected from European
patients with EBA (Italy, Germany, Croatia, Turkey, Czech
Republic) and 51% from Japanese patients with EBA. A total
of 16 of the 48 Japanese EBA sera had already been included
in a previous study by Komorowski et al.10 The controls
included 100 sera from patients with BP, 50 sera from
patients with PV and 50 sera from healthy controls. BP and PV
were diagnosed by clinical phenotype, DIF of perilesional skin
and the serological detection of IgG against BP antigen 180
(BP180)/BP230 or desmoglein (Dsg) (Dsg1 and Dsg3, respec-
tively). This study was conducted in accordance with the Dec-
laration of Helsinki guidelines and approved by the local
ethics committee of the medical faculty of the University of
Marburg, Marburg, Germany.
Immunofluorescence microscopy on saline-split human
skin
Healthy human skin was incubated in a 1 mol L"1 NaCl solu-
tion for 48–72 h. The skin specimens were then washed three
times in phosphate-buffered saline (PBS) for 15 min, embed-
ded in optimum cutting temperature Tissue Tec (Sakure Fine-
tek, Staufen, Germany) and stored at "80 °C. After the
preparation of microscope slides (Superfrost Plus, Langen-
brinck, Emmendingen, Germany) with cryo sections (Micro-
tom Micron HM-560), EBA and control sera were incubated
(a) (b)
(d) (e)
(c)
Fig 1. Clinical differential diagnosis of
autoimmune bullous skin disorders.
(a) Epidermolysis bullosa acquisita (skin);
(b) bullous pemphigoid; (c) laminin-c1
pemphigoid; (d) epidermolysis bullosa
acquisita (oral mucosa); and (e) pemphigus
vulgaris (oral mucosa).
Fig 2. Synopsis of diagnostic assays utilizing
distinct subdomains of collagen VII (Col7).
WB, Western blot; ELISA, enzyme-linked
immunosorbent assay.
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1 : 50 (in PBS) with the human skin cryo sections for 30 min
at room temperature under humid conditions. Sera of patients
with BP and patients with PV and sera of healthy individuals
served as controls. The slides were washed twice with PBS and
incubated for another 30 min with a fluorescein isothio-
cyanate-conjugated AffiniPure F(ab0)2 fragment rabbit antihu-
man IgG antibody (Dianova, Hamburg, Germany) under
humid conditions in the dark. Subsequently, slides were
washed twice again with PBS and the slides were fixed with
mounting medium (Fluorescence Mounting Medium, Dako,
Jena, Germany) and coverslips were added. The final analysis
was performed with a fluorescence microscope (Axiostar,
Zeiss, Jena, Germany).
Sodium dodecyl sulfate gel electrophoresis and Western
blotting
The recombinant fragments of human Col7 NC1(1) (aa17-
aa610), NC1(2) (aa273-857) and NC1(3) (aa611-1253)
(Fig. 2) were produced in a baculovirus-based eukaryotic
expression system as previously described.11 For gel elec-
trophoresis, equal amounts of Col7-NC1 proteins were denat-
urated by Laemmli buffer + b-Mercaptoethanol (95 °C,
5 min) and separated on a 10% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis gel. The WB procedure was
performed as previously described.12 Patient sera were diluted
1 : 200 in PBST (19 PBS + 0!1% Tween-20) and incubated
overnight at 4 °C under shaking conditions. An EBA serum
that tested positive (1 : 200) and a rabbit anti-E-Tag primary
antibody (Abcam, Cambridge, U.K.) served as a positive con-
trol and a serum from a healthy donor was used as a negative
control. Analysis was performed using a digital chemolu-
minescence reader (PEQLAB, Erlangen, Germany).
Collagen VII enzyme-linked immunosorbent assay
The NC1 ELISA [Anti-Type VII Collagen-ELISA (IgG), Euroim-
mun, L€ubeck, Germany] and the NC1/NC2 ELISA (MESACUP
Anti-Type VII Collagen Test, MBL, Nagoya, Japan) were per-
formed according to manufacturers’ protocol. Optical densities
were measured at a wavelength of 450 nm and a reference of
620 nm by photometer Sunrise!-Basic (Tecan, G€oding, Aus-
tria). Calculation of RE mL"1 (Euroimmun ELISA) and
U mL"1 (MBL ELISA) was performed according to the manu-
facturers’ instructions. Samples showing values greater or
equal to 20 RE mL"1 (Euroimmun ELISA) or 6 U mL"1 (MBL
ELISA) were considered to be positive.
Statistics
For each of the four tests (Col7-NC1 ELISA, Col7-NC1/NC2
ELISA, SSS and WB), we calculated estimates and 95% confi-
dence intervals of sensitivity for EBA, BP and PV and for speci-
ficity with respect to healthy control sera, BP/PV controls and
the combination of both control groups. We used the method
detailed by Tango13 to compare the sensitivities and specifici-
ties of Col7-NC1 ELISA, Col7-NC1/NC2 ELISA in addition to
the SSS and WB tests. To explore cut-off values other than
those provided by the manufacturers, receiver operating char-
acteristic (ROC) curves were calculated for the two ELISAs
using the RE mL"1 (Euroimmun ELISA) and U mL"1 (MBL
ELISA) results comparing sensitivity for EBA and specificity
with respect to each of the control groups used. All statistical
analyses were performed using the R program for statistical
computing (R foundation for Statistical Computing, Vienna,
Austria).
Results
Sensitivity of diagnostic assays
Four diagnostic assays were employed to detect anti-Col7 IgG
in the sera of patients with EBA. These included IIF with the
standard substrate SSS, an in-house WB with the recombinant
human CO7-NC1 domain and two commercial ELISA systems
with the human Col7-NC1 and Col7-NC1/NC2 domains,
respectively (Fig. 2). A total of 95 EBA sera were tested. A
total of 100 BP sera, 50 PV sera and 50 healthy control sera
were also tested. The highest sensitivity was obtained with the
NC1 ELISA (89!5%) and the NC1/NC2 ELISA (97!9%) fol-
lowed by WB (85!3%) and IIF with SSS (74!7%). Of note, the
NC1/NC2 ELISA exhibited a significantly higher sensitivity
compared with the NC1 ELISA (P = 0!005) (Table 1). Specifi-
cally, in the analysis of the cohort of 95 patients with EBA,
the NC1/NC2 ELISA delivered 93 positive results and the NC1
ELISA delivered 85 positive results. WB with human Col7-
NC1 revealed a significantly higher sensitivity rate than IIF on
SSS (P = 0!033), whereas the NC1 ELISA and WB results
showed no statistical difference regarding sensitivity
(P = 0!346) (Table 1). Two sera tested positive using WB or
Table 1 Sensitivity of diagnostic assays in epidermolysis bullosa acquisita
P-values (95% CI) SSS WB NC1 ELISA NC1/NC2 ELISA
SSS 0!033 ("0!205 to "0!009) 0!002 (0!061–0!243) 0!000 (0!148–0!329)
WB 0!033 ("0!205 to "0!009) 0!346 ("0!049 to 0!136) 0!001 (0!059–0!212)
NC1 ELISA 0!002 (0!061–0!243) 0!346 ("0!049 to 0!136) 0!005 (0!042–0!157)
NC1/NC2 ELISA 0!000 (0!148–0!329) 0!001 (0!059–0!212) 0!005 (0!042–0!157)
CI, confidence interval; SSS, saline-split skin; WB, Western blot; ELISA, enzyme-linked immunosorbent assay.
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IIF only. Surprisingly, all of the six additionally positive test
results of the NC1/NC2 ELISA originated from European EBA
sera (Italy n = 3, Germany n = 2, Czech Republic n = 1),
which remained below the cut-off value of the NC1 ELISA
(cut-off level 20 RE mL"1).
Specificity of diagnostic assays
The specificity of the diagnostic assays was calculated based
on the analysis of 50 healthy control sera, 50 PV and 100 BP
sera. Overall, the specificity was high (i.e. > 90%) for all
methods tested (Fig. 3). The WB delivered a specificity of
94%, IIF with SSS delivered a specificity of 99%, and the two
ELISA systems delivered a specificity of 99–100%. The NC1
ELISA showed false-positive results for one patient with PV
and one patient with BP (Fig. 4a), while the NC1/NC2 ELISA
was false-positive in one patient with BP (Fig. 4c). Using WB,
three healthy control sera, six BP sera and three PV sera were
considered to be positive. Hence, the healthy control sera
showed the lowest number of false-positive results (n = 3)
and the WB revealed a significantly lower overall specificity
compared with ELISA and IIF (NC1 ELISA, P = 0!004; NC1/
NC2 ELISA, P = 0!002; IIF, P = 0!001) (Table 2).
Diagnostic and predictive power of collagen VII enzyme-
linked immunosorbent assays
ROC analysis [area under the curve (AUC)] revealed no statis-
tical differences between the NC1 ELISA (AUC healthy controls
0!983; AUC BP + PV 0!987) and the NC1/NC2 ELISA (AUC
healthy controls 0!995; AUC BP + PV 0!995) (Fig. 4a, d). We
also tried to correlate anti-Col7 IgG autoantibodies with the
clinical course of selected patients with EBA. In patient 1, as
expected, immune adsorption led to a strong decrease of anti-
Col7 serum IgG levels (T2) but in the course of disease, anti-
Col7 serum IgG increased again (T3) and was associated with
a worsening of the clinical status. As illustrated by Autoim-
mune Bullous Skin Disorder Intensity Score and clinical pic-
tures, anti-Col7 IgG correlated well with disease activity
(Fig. 5a). In contrast, in patient 2, an increase of anti-Col7
IgG was associated with a slight improvement of skin involve-
ment (TP1 > TP2). In was noteworthy that in this patient
antibody titres were very consistent on a high level over time
(TP2 > TP6) (Fig. 5b). In patient 3, complete clinical remis-
sion was accompanied by a strong decrease of anti-Col7 serum
IgG (Fig. 5c). In all three patients with EBA, changes in anti-
Col7 serum IgG concentrations measured by optical density
were comparable between the Col7-NC1 and Col7-NC1/NC2
ELISAs but ran at different levels (Fig. 5a–c). Overall, anti-
Col7 IgG serum concentrations were largely correlated with
the clinical disease activity (Fig. 5a–c).
Discussion
In this international retrospective multicentre study, we inves-
tigated the largest cohort to date of European and Japanese
patients with EBA in order to validate the diagnostic power of
serological assays designed to detect IgG autoantibodies against
Col7, the autoantigen of EBA. Here we demonstrate that two
commercially available human Col7-NC1 ELISAs showed the
highest sensitivity among the in vitro diagnostic assays tested
and were superior to IIF with human SSS and to a WB with
overlapping fragments that span the NC1 subdomain of Col7.
Moreover, one of the two Col7 ELISAs, which additionally
contained the NC2 domain of Col7, showed the highest sensi-
tivity and was thus superior to the Col7-NC1 ELISA.
Epidermolysis bullosa acquisita is a potentially devastating,
chronic relapsing autoimmune bullous disorder of the skin
and mucous membranes that is characterized by a pronounced
and persistent fragility of the skin leading to blisters and ero-
sions with a scarring phenotype.5 The therapeutic mainstay of
EBA are corticosteroids, which are frequently combined with
immunosuppressive drugs such as azathioprine, mycopheno-
late mofetil, methotrexate or cyclophosphamide.14,15 Novel
anti-inflammatory therapies like high-dose intravenous
immunoglobulins, the anti-CD20 monoclonal antibody, ritux-
imab and immunoadsorption have been employed in EBA
treatment with variable success.14,16–18 The inflammatory type
of EBA that clinically resembles BP responds well to immuno-
suppressive drugs. In contrast, mechanobullous EBA is largely
(a)
(b)
Fig 3. Sensitivity and specificity of diagnostic assays utilizing collagen
VII (Col7) in epidermolysis bullosa acquisita. (a) Sensitivity rates of
saline-split skin (SSS), NC1-Western blot (WB) with Col7-NC1, Col7-
NC1 enzyme-linked immunosorbent assay (ELISA) and Co7-NC1/NC2
ELISA. (b) Specificity rates of SSS, WB, NC1-ELISA and NC1/NC2-
ELISA. BP, bullous pemphigoid; PV, pemphigus vulgaris; HC, healthy
controls.
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(a)
(b)
(c)
(d)
Fig 4. Performance of two enzyme-linked immunosorbent assay (ELISA) systems in epidermolysis bullosa acquisita (EBA). (a) Combined box-and-
whisker plots showing collagen VII (Col7) NC1 ELISA results. (b) Receiver operating characteristic (ROC) analysis of Col7-NC1 ELISA results. (c)
Combined box-and-whisker plots showing Col7-NC1/NC2 ELISA results. (d) ROC analysis of Col7-NC1/NC2 ELISA results. BP, bullous
pemphigoid; PV, pemphigus vulgaris; HC, healthy controls; AUC, area under the curve.
Table 2 Specificity of diagnostic assays in epidermolysis bullosa acquisita
P-values (95% CI) SSS WB NC1 ELISA NC1/NC2 ELISA
SSS 0!001 (0!035–0!102) 0!157 ("0!036 to 0!009 0!317 ("0!028 to 0!014)
WB 0!001 (0!035–0!102) 0!004 (0!02–0!092) 0!002 (0!024–0!098)
NC1 ELISA 0!157 ("0!036 to 0!009 0!004 (0!02–0!092) 0!564 ("0!019 to 0!031)
NC1/NC2 ELISA 0!317 ("0!028 to 0!014) 0!002 (0!024–0!098) 0!564 ("0!019 to 0!031)
CI, confidence interval; SSS, saline-split skin; WB, Western blot; ELISA, enzyme-linked immunosorbent assay.
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refractory to immunosuppressive treatment. In addition,
chronic immunosuppressive treatment is associated with major
adverse effects.15,19 Thus, early diagnosis is essential for the
optimal therapeutic and functional management of EBA. The
detection of IgG autoantibodies directed against Col7, which
play an essential pathogenic role (Table 3), is central to the
proper diagnosis of the different clinical EBA vari-
ants.4,10,11,16,20–29 In general, anti-Col7 IgG serum concentra-
tions correlate with the disease status,30,31 which is also
reflected by the longitudinal analyses of three selected patients
with EBA in the present study (Fig. 5).
Currently, in addition to the clinical appearance (which
may be quite heterogeneous), the diagnosis of EBA is estab-
lished based on the detection of tissue-bound (by DIF) and
serum anti-Col7 IgG antibodies (by IIF, WB or ELISA). It has
been estimated that 50–80% of patients with EBA exhibit
both, tissue-bound and circulating anti-Col7 autoantibodies.32
The gold-standard technique for the detection of tissue-bound
IgG is immunoelectron microscopy (IEM), which provides the
highest sensitivity.33 Recently, Terra et al.29 developed a more
refined and highly sensitive DIF analysis of EBA that is based
on the detection of a u-serrated IgG deposition pattern at the
dermoepidermal BMZ. However, at present, the overall
significance of both IEM and DIF serration pattern analysis is
limited as only a few laboratories worldwide provide this
diagnostic technique for EBA. Thus, in current clinical prac-
tice, DIF has proven to be a highly reproducible and robust
technique and is considered to be a reference method for
detection of tissue-bound IgG autoantibodies in EBA.34–36
Consequently, all of the published studies on the sensitivity
and specificity of immunoserological assays in EBA refer to
DIF as the gold standard. However, its diagnostic power may
be overestimated as DIF is less sensitive than IEM and DIF ser-
ration pattern analysis.33 This is reflected in studies by Seta
et al.28 and Terra et al.29 where a positive IEM or serration pat-
tern result served as an inclusion criterion for the assessment
of the diagnosis of EBA. In these studies, the sensitivity of the
NC1/NC2 ELISA was much lower (30% and 54%) compared
with serological studies that defined classical DIF as the gold
standard.
The present study clearly shows that WB using human Col7
and IIF with the standard substrate SSS, are less sensitive than
the commercial Col7 ELISAs. Nevertheless, SSS is a critical
technique for the immunoserological distinction between BP
(epidermal IgG reactivity) and EBA, laminin-c1 pemphigoid
(all dermal IgG reactivity) and mucous membrane pemphigoid
(a)
(b) (c)
Fig 5. Longitudinal analysis of anticollagen
VII (anti-Col7) IgG serum concentrations and
clinical course of patients with epidermolysis
bullosa acquisita (EBA). (a) Patient 1.
Autoimmune bullous skin disorder (ABSIS)
score, anti-Col7 IgG by enzyme-linked
immunosorbent assay (ELISA) (Col7-NC1:RE
mL"1; Col7-NC1/NC2:U mL"1) and
illustration of clinical symptoms (T4, T5, T6
and T7). (b) Patient 2. Anti-Col7 IgG by
ELISA (Col7-NC1:RE mL"1; Col7-NC1/NC2:U
mL"1) and description of clinical symptoms.
(c) Patient 3. Anti-Col7 IgG by ELISA (Col7-
NC1:RE mL"1; Col7-NC1/NC2:U mL"1) and
description of clinical phenotype. IA,
immunoadsorption.
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(dermal and/or epidermal IgG reactivity).37 However, lack of
serum IgG reactivity with SSS does not exclude the diagnosis
of EBA and further immunoserological diagnostics are war-
ranted in cases of clinical suspicion of EBA. Many laboratories
perform IIF on SSS first before further defining the specificity
of antidermal epidermal IgG autoantibodies by ELISA. The SSS
sensitivity rate of 74!7% in the present study is comparable
with previous studies by Chen et al.21 (78%) and Calabresi
et al.20 (83!3%). However, there may be an overestimation of
the diagnostic power of IIF by SSS as several serological stud-
ies of EBA defined IIF positivity as one of the inclusion crite-
ria. The present retrospective study showed that the long-term
storage of EBA sera diminished the sera’s reactivity with SSS as
96!7% of the SSS-tested EBA sera were initially positive but
only 74!7% were positive upon reanalysis. In contrast, Col7
ELISA reactivity was not affected by storage of the sera. This
potential technical bias in evaluating the different serological
techniques should be addressed in a prospective trial.
The sensitivity of WB with Col7-NC1 (85!3%) was similar
to a previous study by Saleh et al.27 (89!8%, based on dermal
extracts), who also found a significantly higher sensitivity for
the Col7-NC1 ELISA. In the case of WB, a reliable comparison
of the methods is not possible owing to the technical varia-
tions used in WB analysis. Overall, because of its limited diag-
nostic power, Col7 WB analysis is of limited value in EBA.
Col7, a typical collagenous protein, is a homotrimer consist-
ing of three a-chains, which form a triple helical collagenous
structure. Each of the trimers contains a NH2-terminal (NC1)
and a COOH-terminal noncollagenous domain (NC2).38 Most of
the patients with EBA exhibit serum IgG autoantibodies against
the immunodominant NC1 domain of Col7.39 In addition, sev-
eral reports have identified Col7-NC2-specific IgG autoantibodies
in EBA.40–45 Saleh et al.27 detected Col7-NC2-specific serum IgG
in 16!2% of the studied EBA sera (n = 49). Is it noteworthy that
in this study, 2% of the patients with EBA showed IgG serum
reactivity against Col7-NC2 exclusively. These findings explain
why the overall sensitivity of the Col7-NC1/NC2 ELISA (MBL) is
superior to the Col7-NC1 ELISA (Euroimmun). It is important to
note that most of the previous studies investigating the perfor-
mance of the Col7-NC1 and Col7-NC1/NC2 ELISA, uniformly
found a very high specificity but variable sensitivity rates. Our
findings are in line with a previous study by Komorowski et al.,10
who found similar rates of sensitivity (91!8%) and specificity
(98!7%) in their cohort of 73 patients with EBA (Col7-NC1
ELISA). Thus, in multicentre studies the described sensitivities
are dependent on the diagnostic methods used to establish the
diagnosis of EBA in the participating centres.
In summary, this study, the largest analysis of European and
Japanese EBA sera to date, demonstrates that two commercial
ELISA systems based on recombinant human Col7-NC1 deliver
the highest sensitivity and specificity for the detection of anti-
Col7-IgG compared with IIF using the standard substrate SSS,
and WB with human Col7-NC1. Furthermore, our findings
clearly show that supplementation of the Col7-NC1 ELISA
with the human Col-NC2 subdomain leads to a significant
increase in the diagnostic power of the Col7 ELISA.
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